Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 593-595

  Nyhuis, Peter W ^a   Gastpar, Markus ^a   Scherbaum, Norbert ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUPRENORPHINE; LITHIUM; TRANYLCYPROMINE; VENLAFAXINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; LETTER; MAJOR DEPRESSION; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; REMISSION; SEDATION; SIDE EFFECT; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; BUPRENORPHINE; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 58149114958     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818638a4     Document Type: Letter

References (13)

1. Weber MW, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol. 1988;3: 225-266.
2. Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann NY Acad Sci. 1982;398:108-112.
3. Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1): 49-57.
4. Fink M, Simeon J, Itil TM, et al. Clinical antidepressant activity of cyclazocine-a narcotic antagonist. Clin Pharmacol Ther. 1970; 11:41-48.
5. Angst J, Autenrieth V, Brem F, et al. Preliminary results of treatment with "-endorphin in depression. In: Usdin E, Bunney WE Jr, KlineS, eds. Endorphins in Mental Health Research. London: Macmillan; 1979:518-528.
6. Gerner RH, Catlin DH, Gorelick A, et al. "- Endorphin. Intravenous infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry. 1980;37:642-647.
7. Gross-Isseroff R, Dillon KA, Israeli M, et al Regionally selective increases in opioid receptor density in the brains of suicide victims. Brain Res. 1990;530:312-316.
8. Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7: 51-54.
9. Cowan A, Lewis JW, eds. Buprenorphine- Combating Drug Abuse With a Unique Opi- oid. Wiley: New York Chichester Brisbane; 1995.
10. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83-91.
11. Hirschfeld RMA, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63: 826-837.
12. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153:985-992.
13. Belenky GL, Holaday JW. The opiate antagonist naloxone modifies the effects of electro- convulsive shock (ECS) on respiration, blood pressure and heart rate. Brain Res. 1979;177: 414-417.